Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Tumor & fibroid embolization · Colorado | Tumor & fibroid embolization · California | |
|---|---|---|
| Surgeons, 2024 | 4 | 34 |
| Medicare fee-for-service cases | 415 | 1,753 |
| Growth since 2019 (Medicare FFS) | +7.6%/yr | +3.4%/yr |
| Forecast cases (Medicare FFS) | 820 in 2030 | 4,240 in 2030 |
| Forecast growth | +12%/yr to 2030 | +16%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 0.9 | 0.5 |
| Medicare Advantage share | 57% | 56% |
| Out of hospital | 70% (+70 pts since 2019) | 40% (+40 pts since 2019) |
| Cases per surgeon | 104 | 52 |
| Top 10 surgeons' share | 100% | 47% |
| Surgeons growing | 1 | 3 |
| New since the base year | 2 | 7 |
| Likely to stop billing it | 0 by 2026 | 8 by 2026 |
| Forecast miss, 1 year (procedure) | 11% | 11% |
| Company payments per surgeon | $53K | $52K |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.